| Bioactivity | LCKLSL hydrochloride is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL hydrochloride potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL hydrochloride also inhibits the generation of plasmin and has anti-angiogenic roles[1]. | ||||||
| Invitro | In human retinal microvascular endothelial cells (RMVECs), treatment with LCKLSL (0-2 mg) inhibits the generation of plasmin and suppresses the VEGF-induced activity of tPA under hypoxic conditions[1]. | ||||||
| Name | LCKLSL hydrochloride | ||||||
| Sequence | Leu-Cys-Lys-Leu-Ser-Leu | ||||||
| Shortening | LCKLSL | ||||||
| Formula | C30H58ClN7O8S | ||||||
| Molar Mass | 712.34 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
LCKLSL hydrochloride
CAS: F: C30H58ClN7O8S W: 712.34
LCKLSL hydrochloride is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL hydrochloride po
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.